Cardiovascular disease remains the leading cause of death among people living with type 1 diabetes, yet the tools doctors use to assess that risk were largely built for a different population. A new study published in Nature Communications examined whether a more sophisticated profiling approach could improve how clinicians identify which patients are most at risk, and the findings reveal both promise and significant complexity in getting that prediction right.
Type 1 diabetes and the limits of standard scoring
Most cardiovascular risk calculators rely on a combination of factors including body weight, blood pressure, cholesterol levels, and blood sugar control. The challenge in type 1 diabetes is that chronically elevated blood sugar can mask or distort the signals these tools depend on, making it harder to distinguish patients who face imminent cardiovascular danger from those who do not.
Researchers analyzed data from roughly 44,000 type 1 diabetes patients drawn from three large European cohorts. Rather than applying a standard scoring model alone, they tested whether layering in a body composition profiling framework, one that measures how well a patient’s biological markers align with their body mass index, could sharpen cardiovascular predictions.
What they found was striking. A specific risk profile defined by misalignment between body weight and key metabolic markers was present in only about 2.5 percent of the general population in earlier research. Among type 1 diabetes patients, that same profile accounted for between 55 and 76 percent of individuals studied. The condition appears to push nearly the entire patient population into a category of metabolic mismatch that standard tools were never designed to detect.
Where the new approach helped and where it fell short
The research team compared two prediction models. The first used an established European cardiovascular risk scoring system. The second added the profiling framework on top of that foundation. The enhanced model showed meaningful improvements in specific scenarios, particularly in predicting major cardiac events among men in two of the three cohorts studied. It also improved prediction of a diabetes related eye complication in both male and female patients across different groups.
However, the improvements were not universal. Results varied by biological sex, by cohort, and by the specific outcome being measured. The researchers were transparent about this inconsistency, framing the findings as encouraging but not yet definitive. Importantly, the approach did not require any additional specialized testing beyond measurements already collected in routine clinical care, meaning it could theoretically be integrated into existing health record systems without adding burden to patients or providers.
What drives the difference in risk
The biological pathways separating higher and lower risk patients within this population appear to trace back to specific markers. Fasting blood sugar levels played a role for both men and women. Systolic blood pressure differences were more prominent among women, while elevated levels of harmful cholesterol were more predictive among men. These distinctions point toward potential targets for tailored prevention, suggesting that the same cardiovascular intervention strategy should not be applied uniformly across all type 1 diabetes patients.
The study also found an association between better blood sugar control and lower risk profiles, which adds nuance to longstanding debates about whether glycemic management alone is sufficient to reduce cardiovascular danger in this population.
Type 1 diabetes risk profiling and the road ahead
The researchers acknowledge meaningful limitations. The data used was cross-sectional, capturing a snapshot in time rather than tracking how individual risk profiles evolve. The study drew exclusively from European populations, limiting how broadly its conclusions can be applied. Longitudinal studies following patients over time will be needed to validate these findings and refine the model further.
Still, the scale of the analysis and the consistency of certain findings suggest that smarter, more individualized cardiovascular risk profiling in type 1 diabetes is not just possible but necessary. The tools currently guiding prevention were built for a population whose biology differs substantially from this one, and the gap that creates may be costing lives.
